Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.24% | 9.22% | 5.53% | 6.17% | 1.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.24% | 9.22% | 5.53% | 6.17% | 1.51% |
| Cost of Revenue | -37.14% | -9.13% | -8.33% | 50.39% | 50.74% |
| Gross Profit | 18.52% | 20.21% | 13.69% | -11.70% | -16.08% |
| SG&A Expenses | 5.84% | -0.86% | -6.22% | -5.15% | -11.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.91% | 1.33% | -2.00% | -3.75% | -11.22% |
| Operating Income | -5.41% | 3.92% | 6.57% | 9.58% | 18.19% |
| Income Before Tax | 24.33% | 56.85% | 42.10% | 41.72% | 57.26% |
| Income Tax Expenses | 11.63% | -19.50% | -100.30% | -102.74% | -105.68% |
| Earnings from Continuing Operations | 24.34% | 56.91% | 42.69% | 42.30% | 57.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.34% | 56.91% | 42.69% | 42.30% | 57.61% |
| EBIT | -5.41% | 3.92% | 6.57% | 9.58% | 18.19% |
| EBITDA | -8.83% | 1.48% | 4.35% | 7.48% | 16.62% |
| EPS Basic | 31.01% | 60.01% | 46.09% | 44.63% | 58.36% |
| Normalized Basic EPS | -4.05% | 6.77% | 10.43% | 14.53% | 23.99% |
| EPS Diluted | 30.95% | 59.97% | 46.18% | 44.72% | 58.41% |
| Normalized Diluted EPS | -3.68% | 7.13% | 10.43% | 14.53% | 23.99% |
| Average Basic Shares Outstanding | 9.52% | 8.23% | 6.17% | 4.06% | 1.90% |
| Average Diluted Shares Outstanding | 10.02% | 8.74% | 6.17% | 4.06% | 1.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |